{"id":"W3005292744","doi":"10.1016/s1470-2045(19)30801-0","title":"Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"Merck Sharp and Dohme; Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Pembrolizumab; Lung cancer; Carboplatin; Internal medicine; Placebo; Response Evaluation Criteria in Solid Tumors; Oncology; Cancer; Surgery; Progressive disease; Chemotherapy; Cisplatin; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001667089,0.001614727,0.003280349,0.0003706902,0.0004473751,0.001084479,0.0009615719,0.002183177,0.005332527],"category_scores_gemma":[0.001924416,0.0006223862,0.002958271,0.0003897744,0.0008937739,0.001196049,0.0004322176,0.003788885,0.0008332466],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007543589,"about_ca_system_score_gemma":0.0006548529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008979715,"about_ca_topic_score_gemma":0.001655972,"domain_scores_codex":[0.9993342,0.000342127,0.00004630505,0.0001297456,0.00004411727,0.0001035087],"domain_scores_gemma":[0.9991447,0.0002750294,0.0002638082,0.00005399086,0.0000475679,0.00021499],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9859113,0.002315536,0.0005000466,0.0007566639,0.00122796,0.00002821142,0.00003367195,0.0001804637,0.001421107,0.00004240771,0.0004007421,0.007181965],"study_design_scores_gemma":[0.9396598,0.05503066,0.003295898,0.00004979161,0.0009328985,0.00003168747,0.00002116642,0.0002338127,0.0002875545,0.00009577761,0.0003446419,0.00001631797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849556,0.009493056,0.0003841189,0.0005458546,0.0005576774,0.001477844,0.0009227821,0.000079423,0.001583515],"genre_scores_gemma":[0.9913017,0.002942515,0.0005651652,0.0007157002,0.000395833,0.001664547,0.0007605075,0.00001461619,0.001639403],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005332527,"threshold_uncertainty_score":0.01783907,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04083119283367594,"score_gpt":0.3379551712156635,"score_spread":0.2971239783819876,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}